Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Berzosertib (M6620) Plus Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer
2020-004231-25Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of berzosertib in small cell lung cancer (SCLC), sponsored by Merck KGaA. Primary endpoint: Objective response rate. Started Feb 2021; status: completed.
02
Drugs
berzosertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2020-004231-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004231-25.